Research Topics
| Kieren A MarrSummaryAffiliation: Oregon Health and Science University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studiesKieren A Marr
Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon 97239, USA
Curr Opin Infect Dis 21:409-14. 2008..Availability of new antifungal drugs has led to creative attempts to prevent infections caused by both yeasts and molds with new antifungal prophylaxis strategies; these studies will be reviewed...
Fungal infections in hematopoietic stem cell transplant recipientsKieren A Marr
Oregon Health and Sciences University, Portland, Oregon 97239, USA
Med Mycol 46:293-302. 2008..This review discusses invasive fungal infections in hematopoietic stem cell transplant recipients, with a focus on the host and the two most common infections, candidiasis and those caused by moulds...
Factors associated with mortality in transplant patients with invasive aspergillosisJohn W Baddley
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL 35294 0006, USA
Clin Infect Dis 50:1559-67. 2010..The purpose of this study was to evaluate factors associated with mortality in transplant patients with IA...
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)Peter G Pappas
Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham Medical Center, Birmingham, Alabama 35294 0006, USA
Clin Infect Dis 50:1101-11. 2010..Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among organ transplant recipients. Multicenter prospective surveillance data to determine disease burden and secular trends are lacking...
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infectionsDavid L Horn
Division of Infectious Diseases, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA
Diagn Microbiol Infect Dis 59:407-14. 2007..As enrollment continues, additional data will be analyzed and published, which will provide valuable information concerning the epidemiology, therapy, and outcomes of IFIs...
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance NetworkJohn W Baddley
Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294 0006, USA
J Clin Microbiol 47:3271-5. 2009..61; P = 0.065). Significant relationships of in vitro MIC to all-cause mortality at 6 and 12 weeks for VOR or AMB were not found...
Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipientsPenelope D Barnes
Division of Infectious Diseases, Oregon Health and Science University, Portland, OR 97239, USA
Br J Haematol 139:519-31. 2007..HSCT recipients often have multiple co-morbidities, and understanding the current outcomes and prognostic variables is therefore important for overall management. This paper reviews historical trends and current data...
Amphotericin B: time for a new "gold standard"Luis Ostrosky-Zeichner
Division of Infectious Diseases, Department of Internal Medicine, Center for the Study of Emerging and Reemerging Pathogens, University of Texas Medical School, Houston, TX, USA
Clin Infect Dis 37:415-25. 2003..Given their superior safety profiles, these preparations can now be considered suitable replacements for AmBD for primary therapy for many invasive fungal infections in clinical practice and research...
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazoleAlexander Imhof
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Clin Infect Dis 39:743-6. 2004..Minimal inhibitory concentrations were > or =1 microg/mL for all available isolates. Yeasts and molds with decreased susceptibility to voriconazole may cause invasive infection in patients treated successfully for aspergillosis...
Combination antifungal therapy for invasive aspergillosisKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Clin Infect Dis 39:797-802. 2004..The results of in vitro studies and animal models suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species...
Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantationKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, USA
Clin Infect Dis 39:S170-5. 2004..An understanding of design issues can help explain current controversies and can assist in development of future prophylaxis studies...
Determination of antifungal drug susceptibilities of Aspergillus species by a fluorescence-based microplate assayS Arunmozhi Balajee
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N D3 100, Seattle, WA 98109, USA
J Antimicrob Chemother 55:102-5. 2005..We have investigated the use of a viability dye, chloromethylfluorescein di-acetate (CMFDA), for antifungal susceptibility testing in a fluorescence microplate (FM) assay format...
Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluidBenjamin Musher
University of Washington, Seattle, WA, USA
J Clin Microbiol 42:5517-22. 2004..GM EIA and qPCR assay add to the sensitivity of BAL for diagnosing IPA in high-risk patients, with excellent specificity. Adjunctive use of these tests may reduce dependence on invasive diagnostic procedures...
Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantationArlo Upton
Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
Biol Blood Marrow Transplant 13:760-4. 2007..No difference in relapsed malignancy was apparent. These data support the hypothesis that fluconazole, when coadministered with CY, decreases CY-related toxicities by inhibiting cytochrome P450 2C9 metabolism...
Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassayKieren A Marr
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Clin Infect Dis 40:1762-9. 2005..Reported sensitivity of the galactomannan enzyme immunoassay as an early diagnostic test for invasive aspergillosis (IA) has been widely variable, ranging from 29% to 100% in earlier clinical studies...
Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatusS Arunmozhi Balajee
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3-100, Seattle, WA 98109, USA
J Clin Microbiol 43:5996-9. 2005..Accurate identification of these organisms may be clinically meaningful, given their potential differences in antifungal susceptibilities...
Clinical significance of azole antifungal drug cross-resistance in Candida glabrataAnil A Panackal
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, 1100 Fairview Ave, D3-100, Seattle, WA 98109, USA
J Clin Microbiol 44:1740-3. 2006..Caution is advised when considering voriconazole therapy for C. glabrata candidemia that occurs in patients with extensive prior azole drug exposure...
Aspergillus ustus infections among transplant recipientsAnil A Panackal
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Emerg Infect Dis 12:403-8. 2006..Based on the clustering of cases in space and time and molecular data, common-source acquisition of this unusual drug-resistant species is possible...
Fusarium infection in hematopoietic stem cell transplant recipientsMarcio Nucci
University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Clin Infect Dis 38:1237-42. 2004..The actuarial survival was 13% (median, 13 days). Persistent neutropenia was the single prognostic factor for death identified by multivariate analysis...
Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogensKieren A Marr
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, 98109, USA
Infect Immun 71:5280-6. 2003..albicans, but not A. fumigatus. The differential role of MyD88 may represent one mechanism by which macrophages regulate innate responses specific to different pathogenic fungi...
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisRaoul Herbrecht
Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
N Engl J Med 347:408-15. 2002..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factorsKieren A Marr
Fred Hutchinson Cancer Research Center Programs in Infectious Diseases and Long term Follow up, Seattle, WA 98109, USA
Blood 100:4358-66. 2002....
Infectious risks and outcomes after stem cell transplantation: are nonmyeloablative transplants changing the picture?Christian Junghanss
Department of Medicine, University of Rostock, School of Medicine, Rostock, Germany
Curr Opin Infect Dis 15:347-53. 2002..Further studies are necessary to define appropriate preventative strategies, and to determine whether patients with ongoing infections might benefit from nonmyeloablative hematopoietic stem cell transplantation...
Long-term care after hematopoietic-cell transplantation in adultsMichael Boeckh
N Engl J Med 347:1625-6; author reply 1625-6. 2002
Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout miceJustina Y Ju
Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Antimicrob Agents Chemother 46:1240-5. 2002..This murine model provided evidence of the efficacy of amphotericin B and caspofungin but not of fluconazole against C. glabrata infection...
Aspergillosis. Pathogenesis, clinical manifestations, and therapyKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue, N D3 100, Seattle, WA 98109, USA
Infect Dis Clin North Am 16:875-94, vi. 2002..This article focuses on the pathogenesis and clinical manifestations of diseases caused by Aspergillus species, with more detailed discussion on therapy of the most morbid manifestation, invasive aspergillosis...
Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioningTakahiro Fukuda
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 102:827-33. 2003..More effective strategies are needed to prevent invasive mold infections, which currently account for a notable proportion of nonrelapse mortality after nonmyeloablative allogeneic HCT...
Voriconazole treatment for less-common, emerging, or refractory fungal infectionsJohn R Perfect
Department of Medicine and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Infect Dis 36:1122-31. 2003..Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections...
New approaches to invasive fungal infectionsKieren A Marr
Fred Hutchinson Cancer Research Center, University of Washington, Seatle, WA 98109, USA
Curr Opin Hematol 10:445-50. 2003..This review will describe these most recent developments with the goal of evaluating new approaches to prevent, diagnose, and treat invasive fungal infections...
Empirical antifungal therapy--new options, new tradeoffsKieren A Marr
N Engl J Med 346:278-80. 2002
Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipientsKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA
Clin Infect Dis 34:909-17. 2002....
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromesBart L Scott
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 14:799-806. 2008..94 [1.0-3.8], P = .05), but not for overall mortality or NRM. We propose that intensified strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who undergo HSCT...
Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortalityArlo Upton
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
Clin Infect Dis 44:531-40. 2007..The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time...
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) CBen de Pauw
Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Clin Infect Dis 46:1813-21. 2008..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...
Phenotypic and genotypic identification of human pathogenic aspergilliS Arunmozhi Balajee
Centers for Disease Control and Prevention, Mycotic Diseases Branch, Atlanta, GA 30333, USA
Future Microbiol 1:435-45. 2006..This review focuses on current and future methods of identifying aspergilli, and implications regarding Aspergillus species/strain identification...
Conidial viability assay for rapid susceptibility testing of Aspergillus speciesS Arunmozhi Balajee
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
J Clin Microbiol 40:2741-5. 2002..e., NCCLS) method. The results of these studies illustrate a method by which AMB susceptibility can be rapidly and reproducibly determined by measuring conidial viability...
Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantationPierre Yves Bochud
Institute for Systems Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
N Engl J Med 359:1766-77. 2008..We examined the role of TLR polymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic hematopoietic-cell transplants...
MyD88 signaling contributes to early pulmonary responses to Aspergillus fumigatusCamille Bretz
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Infect Immun 76:952-8. 2008..Resolution of abnormalities within a 3-day window demonstrates the importance of redundant signaling pathways in mediating pulmonary inflammatory responses to fungi...
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of AmericaThomas J Walsh
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Clin Infect Dis 46:327-60. 2008
Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantationCarol Garcia-Vidal
Fred Hutchinson Cancer Research Center, USA
Clin Infect Dis 47:1041-50. 2008..We sought to determine clinical and biological risk factors for different IMIs during each period (early and late) after allogeneic HSCT...
Infectious complications after autologous CD34-selected peripheral blood stem cell transplantationFulvio Crippa
Fred Hutchinson Cancer Research Center, Seattle Washington 98109-1024, USA
Biol Blood Marrow Transplant 8:281-9. 2002..Because the risk for infections approaches that seen in allogeneic transplant recipients, infection surveillance, diagnostic work-up, and prevention strategies similar to those used in allogeneic recipients are warranted...
Aspergillus galactomannan index: a surrogate end point to assess outcome of therapy?Kieren A Marr
Clin Infect Dis 46:1423-5. 2008
Plasminogen alleles influence susceptibility to invasive aspergillosisAimee K Zaas
Duke University Medical Center, Durham, North Carolina, United States of America
PLoS Genet 4:e1000101. 2008..Furthermore, we demonstrated that plasminogen directly binds to Aspergillus fumigatus. We propose that genetic variation within the plasminogen pathway influences the pathogenesis of this invasive fungal infection...
Aspergillus lentulus sp. nov., a new sibling species of A. fumigatusS Arunmozhi Balajee
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
Eukaryot Cell 4:625-32. 2005..fumigatus and is not able to survive at 48 degrees C. Our findings suggest the presence of a previously unrecognized, potentially drug-resistant Aspergillus species that we designate A. lentulus...
Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factorCelalettin Ustun
The Department of Internal Medicine, Section of Hematology Oncology, Medical College of Georgia, 1120 15th Street, BAA 5407, Augusta, GA 30912 3125, USA
Mycopathologia 162:299-302. 2006..The Microascus genus rarely causes invasive fungal infection in humans and can be very difficult to treat because of the resistance to available antifungal agents...
GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulenceJin Woo Bok
Department of Plant Pathology, University of Wisconsin Madison, 882 Russell Labs, 1630 Linden Drive, Madison, WI 53706, USA
Infect Immun 74:6761-8. 2006..This may indicate that several secondary metabolites are involved in A. fumigatus virulence...
Aspergillosis: spectrum of disease, diagnosis, and treatmentPenelope D Barnes
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Infect Dis Clin North Am 20:545-61, vi. 2006..This article examines the range of infections caused by Aspergillus species, the challenges of diagnosis, and current treatment options...
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxisJohn E Bennett
Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Antimicrob Agents Chemother 48:1773-7. 2004..The rapidity and regularity of the rising resistance indicated that C. glabrata is able to upregulate drug efflux without losing the ability to maintain colonization...
New methods to assess susceptibilities of Aspergillus isolates to caspofunginAlexander Imhof
Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
J Clin Microbiol 41:5683-8. 2003..Agar dilution is simple and reproducible, and results were consistent with the results of more technically demanding techniques. This method may be appropriate for use in the clinical laboratory...
Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant centerTakahiro Fukuda
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 10:494-503. 2004....
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performanceKieren A Marr
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington 98109, USA
J Infect Dis 190:641-9. 2004..The 0.5 cutoff may allow for better performance as an early diagnostic test...
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 casesWilliam J Steinbach
Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
Clin Infect Dis 39:192-8. 2004..29; 95% CI, 0.15-0.56). Voriconazole is likely to be a better treatment choice for A. terreus infection than is a polyene...
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplantsKieren A Marr
Program of Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 103:1527-33. 2004..69). There was no difference in overall or fungal-free survival. Itraconazole appears to prevent IMI in the subset of patients who tolerate the drug; however, toxicities and poor tolerability limit its success as prophylactic therapy...
Cyclophosphamide metabolism is affected by azole antifungalsKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D3 100, Seattle, WA 98109, USA
Blood 103:1557-9. 2004..These data suggest that azole antifungals, through differential inhibition of hepatic cytochrome P-450 isoenzymes, affect CY metabolism and conditioning-related toxicities...
Antifungal therapy for febrile neutropenia: issues in clinical trial designKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N D3 100, Seattle, WA 98119, USA
Curr Opin Investig Drugs 5:202-7. 2004..Here, issues in trial design will be reviewed to address the question: Can (and should) new antifungals be evaluated for treatment of fever during neutropenia?..
Invasive Candida infections: the changing epidemiologyKieren A Marr
University of Washington, School of Medicine, and Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Oncology (Williston Park) 18:9-14. 2004..Increasing evidence underscores the need to carefully evaluate antifungal treatment options, according to both host and therapeutic risks for drug resistance...
Emerging fungal diseasesMarcio Nucci
University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Clin Infect Dis 41:521-6. 2005....
Design issues in studies evaluating diagnostic tests for aspergillosisKieren A Marr
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Clin Infect Dis 41:S381-6. 2005..The widespread availability of a standardized assay may now allow us to address the multiple sources of variability and bias via large, cooperative studies...
Reproducibility of low galactomannan enzyme immunoassay index values tested in multiple laboratoriesArlo Upton
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
J Clin Microbiol 43:4796-800. 2005..However, changes in GMI levels when different kit lots are used, and single samples with low-positive (GMI of 0.5 to 0.7) indices, should be interpreted with caution...
(1-->3) beta -D-glucan assay in the diagnosis of invasive fungal infectionsArlo Upton
Clin Infect Dis 42:1054-6; author reply 1056. 2006
Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosisDavid W Denning
Education and Research Centre, Wythenshawe Hospital and University of Manchester, Academic Department of Medicine and Surgery, Southmoor Road, Manchester M23 9LT, UK
J Infect 53:337-49. 2006..This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA)...
Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control studyChristian Junghanss
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 8:512-20. 2002..This risk is an important consideration for the future development of preventive strategies...
Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the EuroRodrigo Martino
Hematology Department of Sant Pau Hospital, Autonomous University of Barcelona, Spain
Blood 108:2928-36. 2006..001]). These findings may help in the interpretation and design of future studies on secondary prophylaxis of IA after an allo-HSCT...
Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapyMorgan Hakki
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
Antimicrob Agents Chemother 50:2522-4. 2006..Reduced microbial susceptibility to all three echinocandins (caspofungin, anidulafungin, and micafungin) was noted but was not associated with mutations in FKS1...
Aspergillus fumigatus variant with decreased susceptibility to multiple antifungalsS Arunmozhi Balajee
Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Antimicrob Agents Chemother 48:1197-203. 2004..These data suggest the potential presence of a genetically unique, poorly sporulating variant of A. fumigatus that demonstrates decreased susceptibilities to several antifungals...
Research Grants
- Antifungal Drug Resistance in AspergillusKieren Marr; Fiscal Year: 2004..These two aims have been developed to take is closer to the overall goal of decreasing Aspergillus associated mortality by developing more effective, laboratory directed therapeutic strategies. ..
- Immune reconstitution to AspergillusKieren Marr; Fiscal Year: 2007..This information will be valuable for development of strategies to prevent and treat fungal infections in immunocompromised people. ..
- BioRad Galactomannan EIA for Diagnosis of AspergillosisKieren Marr; Fiscal Year: 2007..This project is enabled by the cooperative activities of FHCRC investigators, Bio-Rad Laboratories, and several multicenter networks supported by the CDC, NIAID, and NHLBI. ..
- Inflammatory Responses to Aspergillus FumigatusKieren Marr; Fiscal Year: 2007..fumigatus is coordinated. As this organism is a model lung commensal and pathogen, knowledge generated from these studies will also increase our understanding of mechanisms of specificity of innate host defense. ..
- Genetic Diversity of A. fumigatusKieren Marr; Fiscal Year: 2007..and will develop a stringent molecular typing method that will enhance our knowledge of the biology and population structure of the fungal pathogen A. fumigatus. ..
